MapLight CFO Terminated for Cause Eight Months After IPO
Management crisis
Company Background
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders. It has no revenue and depends entirely on its balance sheet, which stood at $395.2 million in cash, cash equivalents, and investments at March 31, 2026 — a figure management says is sufficient to fund operations through 2027. The net loss for Q1 2026 was $60.7 million.
The company went public on October 28, 2025, raising gross proceeds of $296.3 million through its IPO and a concurrent private placement. It has two programs in the final stretch of Phase 2 testing: ML-007C-MA (brand name ZEPHYR trial, schizophrenia) and ML-004 (IRIS trial, autism spectrum disorder). Both trials completed enrollment in early 2026, with topline results guided for by mid-August 2026.
The clinical pipeline is the company's primary asset. MPLT carries no debt of consequence and has structured operations around delivering those two readouts — making leadership continuity in the run-up to those results particularly relevant to investors.
What Was Disclosed
Vishwas Setia was terminated as Chief Financial Officer on June 18, 2026, effective immediately, "following a review of a human resources violation." The company stated his separation was "wholly unrelated to the Company's financial or operating results, internal controls or clinical programs, or any concerns or disagreements regarding the Company's financial or reporting practices." Setia is not entitled to any severance. Under a Separation Agreement signed the same day, he will receive continued health coverage for himself and his dependents under COBRA for up to three months. The full terms of that agreement will be filed as an exhibit to the company's quarterly report for the period ending June 30, 2026.
The board appointed Jonathan Gillis, previously the Chief Administrative and Accounting Officer, as interim CFO and interim principal financial officer effective June 18, 2026. Gillis will also continue his existing role as principal accounting officer. No timeline for a permanent replacement was disclosed. The company directed readers to Gillis's background as set out in the definitive proxy statement filed April 29, 2026.
Why It Matters
The disclosure describes the conduct triggering the termination only as a "human resources violation" and provides no further detail. The company's explicit statement that the departure is unrelated to financial controls, financial reporting, or clinical programs is a standard protective disclosure required under SEC rules when a principal officer exits under Item 5.02, and it addresses the most severe possible investor concerns directly. However, the nature and scope of the underlying violation remain unknown until, at minimum, the Separation Agreement is filed with the Q2 10-Q.
Gillis now holds both the interim CFO title and the principal accounting officer function simultaneously — a concentration of financial oversight in a single person at a company weeks away from data readouts that represent its primary near-term milestones. The company had $395.2 million in cash at March 31, 2026, and no debt-related governance pressure, so there is no immediate financial fragility that compounds the leadership gap. But MPLT is pre-revenue and its valuation is entirely a function of clinical outcomes, making any distraction in the management team at this stage material context.
Two board members — Robert Malenka, M.D., Ph.D. and Jim Trenkle, Ph.D. — departed at the June 23 annual meeting. Their exits were unconnected to the CFO termination: both notified the board on April 23 of their decision not to stand for re-election, and replacement nominees Martin Babler and Troy Cox were named in the same April filing. Those were routine election-cycle transitions.
